[1]王辰辰,张倩倩,李 静,等.化痰活血方治疗痰瘀痹阻型多发性骨髓瘤疗效及对患者血管内皮生长因子的影响[J].陕西中医,2022,(5):588-591.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.010]
　WANG Chenchen,ZHANG Qianqian,LI Jing,et al.Huatan Huoxue decoction in treatment of multiple myeloma of phlegm and blood stasis syndrome and its effect on VEGF[J].,2022,(5):588-591.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.010]
点击复制

化痰活血方治疗痰瘀痹阻型多发性骨髓瘤疗效及对患者血管内皮生长因子的影响
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2022年5期
页码:
588-591
栏目:
临床研究
出版日期:
2022-05-05

文章信息/Info

Title:
Huatan Huoxue decoction in treatment of multiple myeloma of phlegm and blood stasis syndrome and its effect on VEGF
作者:
王辰辰1; 张倩倩2; 李 静2; 李晓红2
(1.河北中医学院研究生院,河北 石家庄 050200; 2.河北省中医院,河北 石家庄050013)
Author(s):
WANG Chenchen; ZHANG Qianqian; LI Jing; LI Xiaohong
(Graduate School,Hebei University of Chinese Medicine,Shijiazhuang 050200,China)
关键词:
多发性骨髓瘤;  化痰活血方;  骨痛;  生存质量;  血管内皮生长因子
Keywords:
Multiple myeloma;  Huatan Huoxue decoction;  Bone pain;  Quality of life;  VEGF
分类号:
R 733.3
DOI:
DOI:10.3969/j.issn.1000-7369.2022.05.010
文献标志码:
A
摘要:
目的:观察化痰活血方对痰瘀痹阻型多发性骨髓瘤(MM)的疗效及血管内皮生长因子(VEGF)表达水平的影响。方法:选取60例痰瘀痹阻证MM患者,以随机数字表法分为两组。对照组予硼替佐米联合地塞米松(VD方案); 观察组予化痰活血方联合VD方案。4个疗程后比较两组疾病控制率(DCR)、总有效率(ORR)、不良反应发生率、血清VEGF变化水平、骨痛评分(VAS)、卡氏生活质量评分(KPS)和日常生活活动能力评分(ADL)。结果:观察组西医疗效ORR高于对照组(P<0.05),两组DCR比较,差异无统计学意义(P>0.05); 观察组中医证候疗效ORR高于对照组(P<0.05); 治疗后两组VAS及血清VEGF水平均较前降低,且观察组评分和血清VEGF水平低于对照组(P<0.05); 两组KPS、ADL均较前升高,且观察组评分高于对照组(P<0.05); 观察组不良反应发生率低于对照组(P<0.05)。结论:化痰活血方对痰瘀痹阻型MM患者疗效显著,可明显降低VEGF水平和不良反应发生率,改善生存质量。
Abstract:
Objective:To observe the effect of Huatan Huoxue decoction on the clinical efficacy and the level of VEGF in patients with multiple myeloma(MM)of phlegm and blood stasis syndrome.Methods:60 patients with MM of phlegm and blood stasis syndrome treated in department of hematology were randomly divided into two groups.The control group were treated with bortezomib and dexamethasone(VD chemotherapy).The observation group were treated with Huatan Huoxue decoction combined with VD chemotherapy.After 4 courses of treatment,compared the two groups in the disease control rate(DCR),overall response(ORR),incidence of adverse reactions and the changes of VAS,KPS,ADL and VEGF level.Results:The ORR of western medicine curative effect of the observation group were higher than those of the control group(P<0.05).There was no difference in DCR between the two groups(P>0.05).The ORR of TCM syndrome of the observation group was higher than those in the control group(P<0.05).After treatment,VAS of the two groups decreased and these scores of observation group decreased more obviously(P<0.05).The level of VEGF in both groups decreased,and that in the observation group was lower(P<0.05).KPS and ADL of the two groups were higher than before,and these scores of observation group rose more obviously(P<0.05).The incidence of adverse reactions in the observation group was lower than that in the control group(P<0.05).Conclusion:Huatan Huoxue decoction has obvious clinical effect on patients with MM of phlegm and blood stasis syndrome.It can obviously reduce the level of VEGF,the incidence of adverse reactions and improve the quality of life.

参考文献/References:

[1] Mukkamalla S,Kumar R,Malipeddi D.Myeloma bone disease:A comprehensive review[J].International Journal of Molecular Sciences,2021,22(12):6208.
[2] 徐晓坤,曾庆曙,李 婉,等.PCD方案与VAD方案治疗多发性骨髓瘤的疗效及对血清VEGF、β2-MG水平的影响[J].现代生物医学进展,2021,21(6):1112-1115.
[3] 解友邦,方来福,蒋白丽,等.骨髓微血管密度及血管相关生成因子在多发性骨髓瘤中的意义[J].中国实验血液学杂志,2019,27(4):1179-1184.
[4] 石焕英,陈海飞,李群益,等.VEGF及其靶向药物的研究进展[J].上海医药,2020,41(15):4-7,17.
[5] 邢 玉.益肾强骨扶正法联合化疗治疗多发性骨髓瘤临床研究[J].陕西中医,2018,39(7):935-937,946.
[6] 肖汇颖,胡冬菊,王永敏,等.活血逐瘀方联合化疗治疗多发性骨髓瘤临床疗效及对机体免疫功能的影响[J].中华中医药学刊,2020,38(6):160-164.
[7] 中国医师协会血液科医师分会,中华医学会血液学分会,中国医师协会多发性骨髓瘤专业委员会.中国多发性骨髓瘤诊治指南(2020年修订)[J].中华内科杂志,2020,45(5):341-346.
[8] 陈信义,杨文华.中医血液病学[M].北京:中国中医药出版社,2019:207-212.
[9] Snow S,Kirwan JR.Visual analogue scales:A source of error[J].Ann Rheum Dis,1988,47(6):526.
[10] Yildiz CN,Suren M,Demir O,et al.Karnofsky performance scale validity and reliability of turkish palliative cancer patients[J].Turk J Med Sci,2019,49(3):894-898.
[11] 王瑞华.日常生活活动能力(ADL)的测定[J].中级医刊,1994,46(4):7.
[12] Kumar S,Paiva B,Anderson KC,et al.International myeloma working group consensus criteria for response and minimal residualdisease assessment in multiple myeloma[J].Lancet Oncol,2016,17(8):328-346.
[13] 国家食品药品监督管理总局.中药新药临床研究指导原则[S].北京:中国医药科技出版社,2002:227.
[14] Nishida H.Rapid progress in immunotherapies for multiple myeloma:An updated comprehensive review[J].Cancers,2021,13(11):2712.
[15] 朱清红,李德奎,罗 英.血清尿酸、β2微球蛋白和尿液轻链联合检测在多发性骨髓瘤早期诊断中的应用[J].陕西医学杂志,2019,48(9):1235-1237.
[16] 潘 丽,卫若楠,于同月,等.胆南星的临床应用及其用量探究[J].吉林中医药,2021,41(4):532-535.
[17] 唐照琦,李 彪,王秋红,等.胆南星的化学成分、药理作用及相关复方临床应用的研究进展[J].中国药房,2020,31(12):1523-1527.
[18] 王 信,马传江,杨培民,等.白花蛇舌草抗炎、抗肿瘤作用研究进展[J].中国现代应用药学,2020,37(19):2420-2427.
[19] 刘淑艳,黄 畅,林圣云.白花蛇舌草提取物抗多发性骨髓瘤细胞机制研究[J].浙江中西医结合杂志,2019,29(12):970-973.
[20] 梁永超,朱 莹,赵志霞,等.硼替佐米治疗多发性骨髓瘤的研究现状[J].中国临床药理学杂志,2021,37(15):2096-2099.
[21] 吴东升,袁 梅,陈小欢,等.硼替佐米、地塞米松联合环磷酰胺治疗骨髓瘤的临床疗效及对患者不良反应发生的影响[J].广州医药,2021,52(6):18-22.
[22] 苑冬阳,廖爱军.老年多发性骨髓瘤治疗研究进展[J].中华实用诊断与治疗杂志,2019,33(4):403-405.
[23] 费晓莉,陶 黎,熊 梅,等.IL-37、VEGF、LDH和β2-MG在多发性骨髓瘤中的表达及其临床意义[J].重庆医学,2021,50(2):275-279.
[24] Palta A,Manveen K,Anita T,et al.Evaluation of angiogenesis in multiple myeloma by VEGF immunoexpression and microvessel density[J].Journal of Laboratory Physicians,2020,12(1):38-43.
[25] 蒋 峰,柳小芳,高艺文,等.解毒散结方联合化疗治疗晚期胃癌疗效及对患者血管内皮生长因子和受体的影响[J].陕西中医,2021,42(5):582-585.
[26] Ciesielski O,Biesiekierska M,Panthu B,et al.Effects of combined therapy with antiangiogenic and epigenetic drugs on cancer progression[J].Int J Mol Sci,2020,21(7):2606.
[27] 宋亚邛,胡海燕.VEGF、TGF-β1、CA19-9、CA242和DKK1联合检测对早期胰腺癌临床诊断价值研究[J].陕西医学杂志,2020,49(2):237-240.
[28] 张 科,周 俊,李晓明,等.多发性骨髓瘤患者骨髓微龛中CXCL12、CXCR4、VEGF、MVD的表达及与预后的相关性研究[J].中国实验血液学杂志,2020,28(6):1962-1971.
[29] 李 燕,李 静,杨 洁,等.多发性骨髓瘤骨髓病理检测血管内皮生长因子的表达情况[J].河北医药,2016,38(8):1136-1139.

相似文献/References:

[1]李迎巧,高二超,王茂生.杨淑莲治疗多发性骨髓瘤经验[J].陕西中医,2022,(5):628.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.020]
　LI Yingqiao,GAO Erchao,WANG Maosheng.YANG Shulian's experience in treating multiple myeloma with famous traditional Chinese medicine[J].,2022,(5):628.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.020]
[2]刘洺欣,马秋玲,吴 艺,等.中药单体调控PI3K/Akt/mTOR信号通路干预多发性骨髓瘤研究进展[J].陕西中医,2025,46(3):424.[doi:DOI:10.3969/j.issn.1000-7369.2025.03.030]

备注/Memo

备注/Memo:
基金项目:河北省中医药管理局科研计划项目(2019037)
更新日期/Last Update: 2022-05-09